Welcome to our dedicated page for GRI Bio SEC filings (Ticker: GRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GRI Bio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GRI Bio's regulatory disclosures and financial reporting.
GRI Bio, Inc. is a clinical-stage biopharmaceutical company developing immunology-based therapies, led by GRI-0621 for idiopathic pulmonary fibrosis (IPF). For the quarter ended June 30, 2026, it reported a net loss of $1.6 million, narrower than the prior-year period, with operating expenses of $1.6 million driven by reduced research and development spending following completion of a Phase 2a trial of GRI-0621. For the six-month period, the net loss was $3.6 million.
Cash and cash equivalents were $10.9 million as of June 30, 2026, and the accumulated deficit was $55.3 million. The company raised capital mainly through an at-the-market program, selling 1,688,546 shares in the first half of 2026 for $8.2 million in gross proceeds, and additional 2025 public offerings with common stock and warrants. Management believes existing cash funds operations through the second quarter of 2027 under a limited development plan, but states there is substantial doubt about its ability to continue as a going concern without additional financing.
GRI-0621 received FDA Orphan Drug Designation for IPF on June 18, 2026, following a Phase 2a trial that met its primary safety endpoint and showed supportive biomarker and functional trends. The company also continues early work on GRI-0803 for autoimmune diseases. GRI remains a smaller reporting and emerging growth company and discloses an ongoing material weakness in internal controls, with revised controls in place but not yet operating for a sufficient period. A new, stayed Nasdaq Market Value of Listed Securities requirement, if implemented, could pose delisting risk because the company’s MVLS is currently below the proposed threshold.
GRI Bio, Inc. share ownership is updated by three reporting persons — Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC — who jointly report beneficial ownership of 93,005 shares of common stock as of June 30, 2026. This stake equals approximately 4.99% of the common stock, calculated using 1,770,838 shares outstanding as of May 12, 2026 plus shares issuable under certain warrants. The position consists of 90,475 shares issuable upon exercise of Intracoastal Warrant 1 and 2,530 shares issuable upon exercise of Intracoastal Warrant 2. All 93,005 shares are held with shared voting and dispositive power and no sole power. Additional warrant shares are subject to blocker provisions that prevent exercises resulting in beneficial ownership above 4.99%, so 942 shares from Intracoastal Warrant 2 and 3,472 shares from Intracoastal Warrant 3 are excluded from the reported amount. Without these blockers, total beneficial ownership could be 97,419 shares.
GRI Bio, Inc. reported that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead candidate GRI-0621 (tazarotene) for treating idiopathic pulmonary fibrosis, a progressive and ultimately fatal lung disease. This designation is a key regulatory milestone that can support development and potential commercialization.
The status may provide GRI-0621 with potential eligibility for seven years of U.S. market exclusivity upon approval, possible tax credits on qualified clinical expenses, waiver of certain FDA fees and enhanced interaction with the FDA. GRI-0621, a once-daily oral RARβ/γ-selective agonist, previously met primary, secondary and exploratory endpoints in a 35‑patient Phase 2a trial in idiopathic pulmonary fibrosis, most of whom received standard antifibrotic therapy.
GRI Bio, Inc. reported first quarter 2026 results and highlighted new Phase 2a data for its IPF drug candidate GRI-0621. Cash and cash equivalents were approximately $11.0 million as of March 31, 2026, up from about $8.2 million at year-end 2025, which the company expects will fund operations into the second quarter of 2027.
In the 35-patient Phase 2a IPF trial, GRI-0621 added to standard of care showed zero cough versus 25% on placebo, a 76% reduction in dyspnea (4% vs. 17%), no weight loss versus 17% on placebo, and a 61% reduction in diarrhea (13% vs. 33%), with no serious adverse events in the active arm. Exploratory data showed a +99 mL FVC improvement overall and +139 mL in patients on background antifibrotics.
Research and development expenses fell to about $0.4 million from $1.6 million a year earlier as the Phase 2a trial concluded, while general and administrative expenses were approximately $1.6 million versus $1.4 million. Net loss narrowed to roughly $2.0 million from $3.0 million, and the company raised about $6.8 million in gross proceeds through its at-the-market facility.
GRI Bio, Inc. files an Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership. The filing states that, as of March 31, 2026, the Reporting Persons are each deemed to beneficially own 90,475 shares of common stock issuable upon exercise of a warrant held by Intracoastal, representing 5.9% of the company on the stated basis. The filing cites 1,445,029 shares outstanding as of January 29, 2026 used to calculate the percentage and discloses two additional warrants each for 3,472 shares that contain 4.99% blocker provisions. The filing is signed by Mitchell P. Kopin and Daniel B. Asher.
GRI Bio, Inc. reported a Q1 2026 net loss of $1.998M, narrowing from $3.046M a year earlier, as research and development spending fell to $0.361M from $1.64M after completing a Phase 2a trial of lead drug GRI-0621. General and administrative expenses rose to $1.642M, reflecting higher public company costs.
The company ended March 31, 2026 with $11.048M in cash and cash equivalents, helped by $6.8M of gross proceeds from an at-the-market stock program during the quarter. Management believes this cash funds operations into the second quarter of 2027 but warns it is insufficient to complete a Phase 2b trial of GRI-0621 without substantial additional capital. The filing states there is “substantial doubt” about GRI Bio’s ability to continue as a going concern absent new financing.
GRI Bio, Inc. shareholders Intracoastal Capital LLC, Mitchell P. Kopin, and Daniel B. Asher filed an amended Schedule 13G reporting their beneficial ownership of the company’s common stock. The filing focuses on their combined position and the structure of that holding.
As of the close of business on December 31, 2025, the reporting persons may have been deemed to beneficially own 1,097,858 shares of common stock, or 9.99% of the class. This includes 229,347 shares held by Intracoastal and 868,511 shares issuable upon exercise of one warrant. The ownership percentage is based on 10,121,060 shares outstanding as of December 19, 2025 plus the warrant shares counted for this calculation.
The filing explains that additional shares are potentially issuable under several warrants but are currently blocked from exercise by provisions that cap beneficial ownership at 9.99% for one warrant and 4.99% for three others. The investors certify that the securities were not acquired for the purpose of changing or influencing control of GRI Bio.
GRO Bio, Inc. received an amended Schedule 13G from Lincoln Alternative Strategies LLC reporting that it now beneficially owns 0 shares of GRO Bio common stock, representing 0% of the class. The filer confirms it owns 5 percent or less of the company’s common stock.
Lincoln Alternative reports no sole or shared voting or dispositive power over any GRO Bio shares and certifies the securities are not held to change or influence control of the issuer. The filing formally updates regulatory records to reflect the firm’s lack of beneficial ownership.
GRI Bio, Inc. filed a current report describing that it issued a press release on February 4, 2026. The release reiterates the company’s financial results for fiscal year 2025 and summarizes key recent business highlights.
The press release is furnished as Exhibit 99.1 and is not incorporated by reference into other SEC filings or deemed filed for liability purposes.